Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension
Molecular Psychiatry · 2024-09 · 29 (9) · 2657-2665
DOI: 10.1038/s41380-024-02478-9 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Molecular Psychiatry, online erschienen am 25.03.2024. Verfasst von Sanne Y Smith-Apeldoorn und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. s.y.apeldoorn@umcg.nl. Hauptthemen laut MEDLINE: Antidepressive Agents, Depressive Disorder, Treatment-Resistant, Ketamine. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: ZonMw (Netherlands Organisation for Health Research and Development).
Themen: Depression
Abstract (Originalsprache)
About one-third of patients with depression do not achieve adequate response to current treatment options. Although intravenous and intranasal administrations of (es)ketamine have shown antidepressant properties, their accessibility and scalability are limited. We investigated the efficacy, safety, and tolerability of generic oral esketamine in patients with treatment-resistant depression (TRD) in a randomized placebo-controlled trial with open-label extension. This study consisted of 1) a six-week fixed low-dose treatment phase during which 111 participants received oral esketamine 30 mg or placebo three times a day; 2) a four-week wash-out phase; and 3) an optional six-week open-label individually titrated treatment phase during which participants received 0.5 to 3.0 mg/kg oral esketamine two times a week. The primary outcome measure was change in depressive symptom severity, assessed with the Hamilton Depression Rating Scale (HDRS17), from baseline to 6 weeks. Fixed low-dose oral esketamine when compared to placebo had no benefit on the HDRS17 total score (p = 0.626). Except for dizziness and sleep hallucinations scores, which were higher in the esketamine arm, we found no significant difference in safety and tolerability aspects. During the open-label individually titrated treatment phase, the mean HDRS17 score decreased from 21.0 (SD 5.09) to 15.1 (SD 7.27) (mean difference -6.0, 95% CI -7.71 to -4.29, p < 0.001). Our results suggest that fixed low-dose esketamine is not effective in TRD. In contrast, individually titrated higher doses of oral esketamine might have antidepressant properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. s.y.apeldoorn@umcg.nl.
- Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
- Department of Psychiatry, PsyQ Haaglanden, Parnassia Psychiatric Institute, The Hague, The Netherlands.
- Depression Expertise Center, Pro Persona Mental Health Care, Nijmegen, The Netherlands.
- Behavioral Science Institute, Radboud University, Nijmegen, The Netherlands.
- Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
ORCID-Profile: Robert A Schoevers
Förderung
- ZonMw (Netherlands Organisation for Health Research and Development)
Zitieren
APA
Smith-Apeldoorn, S. Y., Veraart, J. K. E., Kamphuis, J., Spijker, J., van der Meij, A., van Asselt, A. D. I., Aan Het Rot, M., & Schoevers, R. A. (2024). Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension. Molecular Psychiatry, 29(9), 2657-2665. https://doi.org/10.1038/s41380-024-02478-9
Vancouver
Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, Spijker J, van der Meij A, van Asselt ADI, et al. Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension. Molecular Psychiatry. 2024;29(9):2657-2665. doi:10.1038/s41380-024-02478-9
BibTeX
@article{SmithApeldoorn2024,
author = {Smith-Apeldoorn, Sanne Y and Veraart, Jolien K E and Kamphuis, Jeanine and Spijker, Jan and van der Meij, Annemarie and van Asselt, Antoinette D I and Aan Het Rot, Marije and Schoevers, Robert A},
title = {Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension},
journal = {Molecular Psychiatry},
year = {2024},
volume = {29},
number = {9},
pages = {2657--2665},
doi = {10.1038/s41380-024-02478-9}
}
EUVIMED